120 related articles for article (PubMed ID: 36693138)
1. Early Antiretroviral Therapy Reduces Severity but Does Not Eliminate Neurodevelopmental Compromise in Children With HIV.
Benki-Nugent S; Tamasha N; Mueni A; Laboso T; Wamalwa DC; Njuguna I; Gómez L; Tapia K; Bangirana P; Maleche-Obimbo E; Boivin MJ; John-Stewart GC
J Acquir Immune Defic Syndr; 2023 May; 93(1):7-14. PubMed ID: 36693138
[TBL] [Abstract][Full Text] [Related]
2. Lower Neurocognitive Functioning in HIV-Exposed Uninfected Children Compared With That in HIV-Unexposed Children.
Benki-Nugent SF; Yunusa R; Mueni A; Laboso T; Tamasha N; Njuguna I; Gómez L; Wamalwa DC; Tapia K; Maleche-Obimbo E; Bangirana P; Boivin MJ; John-Stewart GC
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):441-447. PubMed ID: 35202050
[TBL] [Abstract][Full Text] [Related]
3. Neurodevelopment of children who are HIV-exposed and uninfected in Kenya.
Bulterys MA; Njuguna I; King'e M; Chebet D; Moraa H; Gomez L; Onyango A; Malavi K; Nzia G; Chege M; Neary J; Wagner AD; Lawley KA; Wamalwa D; Benki-Nugent S; John-Stewart G
J Int AIDS Soc; 2023 Oct; 26 Suppl 4(Suppl 4):e26149. PubMed ID: 37909174
[TBL] [Abstract][Full Text] [Related]
4. Developmental Disorder Probability Scores at 6-18 Years Old in Relation to In-Utero/Peripartum Antiretroviral Drug Exposure among Ugandan Children.
Awadu JE; Sikorskii A; Zalwango S; Coventry A; Giordani B; Ezeamama AE
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329408
[TBL] [Abstract][Full Text] [Related]
5. Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation.
van Wyhe KS; Laughton B; Cotton MF; Meintjes EM; van der Kouwe AJ; Boivin MJ; Kidd M; Thomas KG
J Int AIDS Soc; 2021 Jul; 24(7):e25734. PubMed ID: 34259393
[TBL] [Abstract][Full Text] [Related]
6. Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children.
Gómez LA; Crowell CS; Njuguna I; Cranmer LM; Wamalwa D; Chebet D; Otieno V; Maleche-Obimbo E; Gladstone M; John-Stewart G; Benki-Nugent S
Pediatr Infect Dis J; 2018 Sep; 37(9):916-922. PubMed ID: 29438131
[TBL] [Abstract][Full Text] [Related]
7. Higher Hospitalization Rates in Children Born HIV-exposed Uninfected in British Columbia, Canada, Between 1990 and 2012.
Li SNJ; Albert A; Piske M; Janssen PA; Alimenti A; Jesson J; Côté HCF; Sauvé L
Pediatr Infect Dis J; 2022 Feb; 41(2):124-130. PubMed ID: 34711783
[TBL] [Abstract][Full Text] [Related]
8. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study.
le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Nguyen KK; Zerbe A; Kroon M; Myer L
Lancet Child Adolesc Health; 2019 Apr; 3(4):234-244. PubMed ID: 30773459
[TBL] [Abstract][Full Text] [Related]
9. High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.
Benki-Nugent SF; Martopullo I; Laboso T; Tamasha N; Wamalwa DC; Tapia K; Langat A; Maleche-Obimbo E; Marra CM; Bangirana P; Boivin MJ; John-Stewart GC
J Acquir Immune Defic Syndr; 2019 May; 81(1):102-109. PubMed ID: 30768490
[TBL] [Abstract][Full Text] [Related]
10. Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study.
Puthanakit T; Ananworanich J; Vonthanak S; Kosalaraksa P; Hansudewechakul R; van der Lugt J; Kerr SJ; Kanjanavanit S; Ngampiyaskul C; Wongsawat J; Luesomboon W; Vibol U; Pruksakaew K; Suwarnlerk T; Apornpong T; Ratanadilok K; Paul R; Mofenson LM; Fox L; Valcour V; Brouwers P; Ruxrungtham K;
Pediatr Infect Dis J; 2013 May; 32(5):501-8. PubMed ID: 23263176
[TBL] [Abstract][Full Text] [Related]
11. Growth differences by school-age and adolescence according to in utero and peripartum antiretroviral therapy exposure among Ugandan children.
Awadu JE; Zalwango SK; Sikorskii A; Giordani B; Bovin MJ; Musoke PM; Ezeamama AE
Medicine (Baltimore); 2023 Jan; 102(4):e32677. PubMed ID: 36705393
[TBL] [Abstract][Full Text] [Related]
12. The effect of antiretroviral therapy initiation on vitamin D levels and four oral diseases among Kenyan children and adolescents living with HIV.
Seminario AL; Kemoli A; Fuentes W; Wang Y; Rajanbabu P; Wamalwa D; Benki-Nugent S; John-Stewart G; Slyker JA
PLoS One; 2022; 17(10):e0275663. PubMed ID: 36227876
[TBL] [Abstract][Full Text] [Related]
13. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Boivin MJ; Maliwichi-Senganimalunje L; Ogwang LW; Kawalazira R; Sikorskii A; Familiar-Lopez I; Kuteesa A; Nyakato M; Mutebe A; Namukooli JL; Mallewa M; Ruiseñor-Escudero H; Aizire J; Taha TE; Fowler MG
Lancet HIV; 2019 Aug; 6(8):e518-e530. PubMed ID: 31122797
[TBL] [Abstract][Full Text] [Related]
14. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy.
Laughton B; Cornell M; Kidd M; Springer PE; Dobbels EFM; Rensburg AJV; Otwombe K; Babiker A; Gibb DM; Violari A; Kruger M; Cotton MF
J Int AIDS Soc; 2018 May; 21(5):e25106. PubMed ID: 29722482
[TBL] [Abstract][Full Text] [Related]
15. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa.
Lowick S; Sawry S; Meyers T
Psychol Health Med; 2012; 17(5):599-610. PubMed ID: 22313239
[TBL] [Abstract][Full Text] [Related]
16. Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV.
Kerr SJ; Puthanakit T; Vibol U; Aurpibul L; Vonthanak S; Kosalaraksa P; Kanjanavanit S; Hansudewechakul R; Wongsawat J; Luesomboon W; Ratanadilok K; Prasitsuebsai W; Pruksakaew K; van der Lugt J; Paul R; Ananworanich J; Valcour V;
AIDS Care; 2014; 26(11):1327-35. PubMed ID: 24878112
[TBL] [Abstract][Full Text] [Related]
17. Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial.
Njuguna IN; Cranmer LM; Otieno VO; Mugo C; Okinyi HM; Benki-Nugent S; Richardson B; Stern J; Maleche-Obimbo E; Wamalwa DC; John-Stewart GC
Lancet HIV; 2018 Jan; 5(1):e12-e22. PubMed ID: 29150377
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya.
Nyandiko WM; Ayaya S; Nabakwe E; Tenge C; Sidle JE; Yiannoutsos CT; Musick B; Wools-Kaloustian K; Tierney WM
J Acquir Immune Defic Syndr; 2006 Dec; 43(4):418-25. PubMed ID: 17099313
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of early versus late initiated antiretroviral treatment in adolescents with perinatal HIV-1 infection.
Magodoro IM; Guerrero-Chalela CE; Claggett B; Jermy S; Samuels P; Myer L; Zar HJ; Jao J; Ntsekhe M; Siedner MJ; Ntusi NAB
Sci Rep; 2024 Jun; 14(1):14234. PubMed ID: 38902326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
